



**BAL PHARMA LIMITED**  
CIN: L85110KA1987PLC008363

Regd Office:21-22,Bommasandra Industrial Area, Anekal Taluq, Bangalore -560099  
**STANDALONE & CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER ENDED 30.06.2018**

Sl No	Particulars	Standalone				Consolidated			
		QUARTER ENDED		YEAR ENDED		QUARTER ENDED		YEAR ENDED	
		30.06.2018	31.03.2018	30.06.2017	31.03.2018	30.06.2018	31.03.2018	30.06.2017	31.03.2018
		(Unaudited)	(Audited)	(Unaudited)	(Audited)	(Unaudited)	(Audited)	(Unaudited)	(Audited)
1	Revenue from Operations	5,273.87	5,792.97	4,542.88	20,984.74	5,356.74	5,890.68	4,598.39	21,175.28
2	Other Income	76.28	-25.44	78.19	163.92	76.11	-23.63	75.34	157.49
3	Total Revenue from operations (1+2)	5,350.14	5,767.53	4,621.07	21,148.66	5,432.85	5,867.05	4,673.73	21,332.77
4	Expenses								
	a) Cost of materials consumed	2,979.30	3,620.08	2,283.55	10,491.63	2,979.30	3,424.07	2,283.55	10,295.63
	b) Purchases of Stock-In-Trade	81.62	229.45	160.46	694.10	87.44	273.69	186.19	760.48
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-90.75	-1,035.98	-483.60	-1,123.61	-72.83	-994.63	-502.03	-1,119.83
	d) Employee benefit expense	1,145.26	1,197.87	1,131.78	4,462.91	1,194.96	1,251.71	1,214.73	4,717.64
	e) Finance Costs	265.79	265.14	184.83	924.32	265.86	267.00	185.22	927.21
	f) Depreciation and amortization expense	143.09	196.27	144.80	672.80	144.12	197.46	145.64	677.11
	g) Other Expenses	700.63	1,025.75	1,099.73	4,181.04	781.33	1,360.98	1,195.98	4,786.23
	<b>Total expenses</b>	5,224.94	5,498.58	4,521.55	20,303.19	5,380.18	5,780.28	4,709.28	21,044.47
5	<b>Profit before exceptional Items and tax (3-4)</b>	<b>125.20</b>	<b>268.95</b>	<b>99.52</b>	<b>845.46</b>	<b>52.67</b>	<b>86.78</b>	<b>-35.55</b>	<b>288.30</b>
6	Exceptional items								
7	<b>Profit Before Tax (5-6)</b>	<b>125.20</b>	<b>268.95</b>	<b>99.52</b>	<b>845.46</b>	<b>52.67</b>	<b>86.78</b>	<b>-35.55</b>	<b>288.30</b>
8	Tax Expense	-108.31	121.87	28.41	251.63	-105.73	121.03	28.41	250.65
9	<b>Net Profit for the period (7-8)</b>	<b>233.51</b>	<b>147.09</b>	<b>71.12</b>	<b>593.83</b>	<b>158.40</b>	<b>-34.25</b>	<b>-63.96</b>	<b>37.65</b>
10	Other Comprehensive Income:								
	a) (i) Items that will be reclassified to Profit or Loss	-	-	-	-	-	-	-	-38.37
	(ii) Income tax relating to items that will not be reclassified to profit or	-	-	-	-	-	-	-	-
	b) (i) Items that will not be reclassified to Profit or Loss	-	9.56	-12.88	-29.09	-	52.75	-12.79	14.37
	(ii) Income tax relating to items that will not be reclassified to profit or	-	-	-	-	-	-	-	-
	<b>Total other comprehensive Income</b>	-	<b>9.56</b>	<b>-12.88</b>	<b>-29.09</b>	-	<b>52.75</b>	<b>-12.79</b>	<b>-24.00</b>
11	Total Comprehensive Income for the period (9+10)	233.51	156.65	58.24	564.74	158.40	18.49	-76.75	13.65
12	Paid up Equity Share Capital (Face value of Rs. 10 per share)	1,417.24	1,417.24	1,417.24	1,417.24	1,417.24	1,417.24	1,417.24	1,417.24
13	Other Equity								
14	Earnings per share (of Rs. 10/- each )(not annualized)								
	a) Basic	1.65	1.11	0.50	3.98	1.12	0.13	-0.54	0.10
	b) Diluted	1.65	1.11	0.50	3.98	1.12	0.13	-0.54	0.10

Notes:

- 1 The above Un-Audited financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 10th August, 2018. The financial results are subjected to limited review by the Statutory Auditors of the
- 2 The Un-Audited financial results have been prepared in accordance with the Inda AS , notified under the Companies (Indian Accounting Standards) Rules, 2015.
- 3 As per Regulation 33 of SEBI(LODR) Regulations, Company opted to submit standalone financials to the stock exchanges. However, unabridged financial statements will be uploaded on our website.
- 4 As the Company deals with single product i.e., pharmaceuticals, segment wise figures are not furnished.
- 5 Effective April 1, 2018 the Company adopted Ind AS 115 "Revenue from Contracts with Customers" as such the effect of adaption is insignificant on financial statement and hence accordingly the comparatives have not been retrospectively adjusted.

The Figures for the corresponding previous period have been regrouped/ restated, wherever necessary.

**For Bal Pharma Limited**

Place: Bengaluru

S/d

Date: 10.08.2018

Shailesh D Siroya  
Managing Director